Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
1.050
-0.040 (-3.67%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Virax Biolabs Group Employees
Virax Biolabs Group had 17 employees as of March 31, 2024. The number of employees increased by 6 or 54.55% compared to the previous year.
Employees
17
Change (1Y)
6
Growth (1Y)
54.55%
Revenue / Employee
$4,992
Profits / Employee
-$387,077
Market Cap
4.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 17 | 6 | 54.55% |
| Mar 31, 2023 | 11 | 6 | 120.00% |
| Mar 31, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VRAX News
- 27 days ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
- 5 weeks ago - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes - PRNewsWire
- 6 weeks ago - Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting - PRNewsWire
- 7 weeks ago - Virax Biolabs to Present at 19th World Immune Regulation Meeting - PRNewsWire
- 2 months ago - Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy - PRNewsWire
- 3 months ago - Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Accesswire
- 3 months ago - Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Accesswire
- 4 months ago - Virax Biolabs' CEO James Foster Issues Letter to Shareholders - PRNewsWire